SpiroChem, a Swiss fine chemicals company specialising in creating novel building blocks for use in drug discovery by its pharma and biotech partners, has announced the appointment of Dr Anthony Baxter to the Board of Directors with immediate effect and the relocation of its business to facilities in Basel, Switzerland.
Dr Anthony Baxter joins the Company from Cyprotex, a leading supplier of DMPK services to the pharma and biotech community, where he held the position of CEO before its acquisition by Evotec in 2016 (£55m).
Prior to this, Dr Baxter was the founding CEO of Argenta Discovery, a leading drug discovery services and proprietary therapeutics company.
In addition, Dr Baxter was CSO of Oxford Asymmetry International and helped build the business from an early stage company, to its flotation on the London Stock Exchange and then to its eventual merger with Evotec in 2000 (£316m).
Dr Baxter graduated from the University of Manchester in Salford, UK. Following this, he worked as a medicinal chemist with more than 12 years senior level experience at GSK and Ciba-Geigy UK (now Novartis).
With a growing reputation as a trusted partner of choice in the life sciences industry and increasing demand for SpiroChem’s innovative products, the Company has relocated to new, enlarged facilities in the Rosental Area of Basel. Previously the Company was based at world-renowned ETH Zürich.
Dr Baxter, Director at SpiroChem, said: “I am delighted to join the Board of SpiroChem as the Company enters the next key phase of development on the road towards becoming a leading innovation and drug discovery partner to the pharmaceutical industry. I very much look forward to working with the team and leveraging my industry knowledge and experience as a chemist to SpiroChem’s full advantage.”